Figure - available via license: Creative Commons Attribution 4.0 International
Content may be subject to copyright.
Reported side effects *.
Source publication
Myopathies fall under the umbrella of rare diseases, however, muscle pain is a relevant, under-recognized symptom with limited treatment options. Carbamazepine is an oral sodium channel blocker approved for the treatment of seizures and neuropathic pain. In 54 individuals receiving carbamazepine for muscle pain, we retrospectively assessed the subj...
Contexts in source publication
Context 1
... significantly elevated Z-Score for MPT indicated mechanical hyperalgesia, and a significantly lower Z-Score in VDT showed vibrotactile hypoesthesia. We observed significantly more paradoxical heat sensations (PHS), and the significantly elevated DMA indicated allodynia in our muscle pain cohort (Figure 2, Supplementary Table S2). Figure 2. Sensory profiles. ...Context 2
... percent stopped taking carbamazepine due to side effects. The most commonly reported side effects leading to drug discontinuation were elevated liver enzymes, nausea, or fatigue (double entries possible, Table 2). Other reasons for stopping carbamazepine intake were either no improvement of muscle pain (11%) or interactions with birth control and pregnancy (2%). ...Similar publications
Introduction
Chronic muscle pain is common in myotonic dystrophies (DM). Little is known about its pathophysiology. We aimed to investigate the characteristics of the neuropathic pain component contributing contributes to the pathogenesis of chronic pain in DM.
Methods
Twenty-one DM1 and 32 DM2 patients completed pain questionnaires (Brief pain in...
Citations
... Most voltage-gated sodium channels are expressed in peripheral C and A nerve fibres. These channels are inhibited by carbamazepine [72]. It has also been demonstrated that oxcarbazepine, a derivative of carbamazepine with enhanced safety and tolerability, is helpful in lowering discomfort associated with DPN [73]. ...
Diabetic neuropathy is a persistent consequence of the biochemical condition known as diabetes mellitus. As of now, the identification and management of diabetic neuropathy continue to be problematic due to problems related to the safety and efficacy of existing therapies. This study examines biomarkers, molecular and cellular events associated with the advancement of diabetic neuropathy, as well as the existing pharmacological and non-pharmacological treatments employed. Furthermore, a holistic and mechanism-centric drug repurposing approach, antioxidant therapy, Gene and Cell therapies, Capsaicin and other spinal cord stimulators and lifestyle interventions are pursued for the identification, treatment and management of diabetic neuropathy. An extensive literature survey was done on databases like PubMed, Elsevier, Science Direct and Springer using the keywords “Diabetic Neuropathy”, “Biomarkers”, “Cellular and Molecular Mechanisms”, and “Novel Therapeutic Targets”.Thus, we may conclude that non-pharmacological therapies along with palliative treatment, may prove to be crucial in halting the onset of neuropathic symptoms and in lessening those symptoms once they have occurred.
... The dosage of the drug is mainly low. Administration of carbamazepine after PBC has a stronger combination effect, which can effectively relieve the degree of pain and improve the quality of life of patients [20]. ...
Objective: To investigate the effect of percutaneous balloon compression combined with carbamazepine on patients with Trigeminal Neuralgia (TN). Methods: The clinical data of 126 patients with TN admitted to our hospital from January, 2021 to January, 2022 were retrospectively analyzed. All patients underwent percutaneous balloon compression in our hospital. The patients were divided into a control group and an observation group, according to whether they continued to take carbamazepine after surgery. The general demographic data of patients, such as gender, age, family income, education level, pain site, diseased nerve, course of disease, and duration of pain were collected. Propensity score matching was used to balance the baseline data of the two groups, and the quality of life, treatment effect, and complications of the two groups were compared after matching. Results: After treatment, the total effective rate of the observation group (95.00%) was higher than that of the control group (70.00%) (p < 0.05). Before treatment, there were no significant differences in the scores for quality of life dimensions between the two groups (p > 0.05). After treatment, the scores for each quality of life dimension in the observation group were higher than those in the control group. After treatment, the incidence of complications in the observation group (7.50%) was lower than that in the control group (30.00%) (p < 0.05). Conclusions: Percutaneous balloon compression combined with carbamazepine can effectively enhance the treatment of patients by improving their quality of life and reducing the occurrence of complications. These results can improve the clinical management of TN.
... It is also potentially effective as initial monotherapy for tonic-clonic seizures with generalized-onset [54,55]. Additionally, CBZ was approved as a treatment option for neuropathic pain in trigeminal neuralgia and diabetic neuropathies [56] and as a second-line treatment in psychiatric disorders such as bipolar disorder [57]. CBZ, in particular, binding VGSCs, increases fast inactivation, thus modifying ionic currents. ...
... CBZ, in particular, binding VGSCs, increases fast inactivation, thus modifying ionic currents. Common side effects include sleep disturbances, vomiting, irritability, rash, ataxia, and diplopia [56,58]. ...
Background
Epilepsy is a chronic brain condition affecting over 50 million people worldwide. Several new anti-seizure medications (ASMs) have been introduced to treat epilepsy in recent decades.
Objective
Nearby the specific therapeutic action, ASMs, like other types of pharmacotherapy, can produce various side effects. In this review, we shall analyze the different pharmaceutical classes of ASMs, their mechanism of action, and their interaction with the respiratory system.
Methods
This manuscript is based on a retrospective review of English publications indexed by Pubmed, UpToDate and datasheets published by the European Medicines Agency and the Food and Drug Administration (FDA), using various terms reminiscent of ASMs and pulmonary function.
Results
ASMs act on organism homeostasis in different ways, acting on lung function directly and indirectly and playing a protective or damaging role. A damaging direct lung involvement ranged from infections, hypersensitivity reactions, and respiratory depression to other structured pulmonary diseases. Meanwhile, a damaging indirect effect, might be constituted by pulmonary artery hypertension. On the other hand, a protective effect might be the expression of developmental processing, decreasing airway remodelling in asthma patients, vascular remodelling in pulmonary hypertension and, nonetheless, anti-inflammatory and immunomodulatory actions.
Conclusion
An adequate awareness of ASMs effects on the respiratory system seems essential for better managing frail individuals or/and those predisposed to respiratory disorders to improve our patients' clinical outcomes.
Carbamazepine is a first-choice anticonvulsant, and its medication is typically well tolerated when compared to lithium and valproic acid. Patients of Alzheimer’s Disease who are administered carbamazepine tend to develop acute tubulointerstitial nephritis. In this study, we established an Alzheimer’s model using scopolamine in Sprague Dawley rats to find out the nephroprotective effect of matricin (a bioactive sesquiterpene isolated from chamomile flowers) against carbamazepine-induced acute tubulointerstitial nephritis and its underlying mechanism of action. Scopolamine (16 mg/kg) was intraperitoneally injected for induction of Alzheimer’s disease on the 28th day whereas carbamazepine (25 mg/kg) was given daily to induce acute tubulointerstitial nephritis. Treatment with matricin inhibited carbamazepine-induced mRNA expressions of RAS-ERK-MEK-JAK2-STAT3, cytokines (IL-1β, TNF-α, and IL-6), and restored the optimal levels of biomarkers of oxidative stress (MDA, SOD and CAT). Further, matricin treatments reinstated biomarkers of kidney function (creatinine, uric acid, and blood urea nitrogen), and refurbished the levels of MDA, SOD, and CAT. Histopathological analyses indicated that there was systemic dilation, tubular necrosis, interstitial edema, and glomerulus nephritis in the medulla region of the kidneys in rats with Alzheimer’s disease that received carbamazepine only. Treatment with matricin reconsolidated histopathology, and only mild glomerulus nephritis were observed in rats with Alzheimer’s disease. These results suggest that matricin could be utilized as a co-supplement with carbamazepine for the treatment of patients with Alzheimer’s disease to minimize the risk of kidney damage.
